Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.37 |
| ▸ | P2RX7 | Q99572 | 3/20 | 0.33 |
| ▸ | HRH1 | P35367 | 1/20 | 0.33 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.31 |
| ▸ | ACP1 | P24666 | 1/20 | 0.31 |
| ▸ | CD38 | P28907 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12310544 | 0.78 | — | — | |
| SCHEMBL5767335 | 0.76 | — | — | |
| SCHEMBL28170638 | 0.76 | — | — | |
| SCHEMBL23079318 | 0.74 | HRH1 (0.33) | HRH1HDAC8 | |
| SCHEMBL171566 | 0.73 | HRH1 (0.33) | HRH1HDAC8 | |
| SCHEMBL84600 | 0.72 | — | — | |
| SCHEMBL27849652 | 0.70 | P2RX7 (0.32) | P2RX7HRH1 | |
| SCHEMBL2091443 | 0.70 | HRH1 (0.32) | HRH1 | |
| SCHEMBL28003526 | 0.70 | — | — | |
| SCHEMBL28934730 | 0.69 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10189835-B2 | Derivatives and methods of treating hepatitis B infections | NOVIRA THERAPEUTICS, INC. (US) | 2019-01-29 | — | — | US | disclosed |
| US-20180127415-A1 | DERIVATIVES AND METHODS OF TREATING HEPATITIS B INFECTIONS | NOVIRA THERAPEUTICS, INC. | 2018-05-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10189835-B2 | Derivatives and methods of treating hepatitis B infections | HAVCR2, PYGL, HCCS | TAAR1 4518/4885P2RX7 3671/4885HRH1 2524/4885 |
| US-20180127415-A1 | DERIVATIVES AND METHODS OF TREATING HEPATITIS B INFECTIONS | HAVCR2, PYGL, HCCS | TAAR1 4518/4885P2RX7 3671/4885HRH1 2524/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.